Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer

Trilaciclib is a recently approved cyclin-dependent kinase 4/6 inhibitor that is designed to decrease the incidence of chemotherapy-induced myelosuppression in adult patients with extensive-stage small-cell lung cancer receiving chemotherapy. Currently, this first-in-class therapy raises two open is...

Descripción completa

Detalles Bibliográficos
Autores principales: Powell, Kerrington, Prasad, V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379686/
https://www.ncbi.nlm.nih.gov/pubmed/34419683
http://dx.doi.org/10.1016/j.tranon.2021.101206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379686/
https://www.ncbi.nlm.nih.gov/pubmed/34419683
http://dx.doi.org/10.1016/j.tranon.2021.101206

Ejemplares similares